Company Long-Term Loans and Borrowings: NeuroBo (NRBO)

Brandmark of NeuroBo Pharma (NRBO)

Investing in NeuroBo Pharmaceuticals (NRBO) carries the risk of drug testing failures and intense pressure from industry behemoths. However, successful development would generate colossal profits due to the low-cost production of patented formulas. The business targets growing demand within the metabolic disorders niche, where the indicator stands at 0.00. This price chart illustrates the trading dynamics, revealing the market value of this biotech project.

NeuroBo Pharmaceuticals Inc (NRBO) Company Long-Term Debt: for the period 07/04/2022 - 12/07/2024

NeuroBo - analytical breakdowns and key metrics (NRBO)

- market price and analyst price targets:
Stock Price neurobopharma.com|NRBO - Price Target Chart
- company stock exchange capitalization indicators:
Market Value NeuroBo Pharmaceuticals|NRBO - Total Company Value
- book capitalization information:
Net Asset Value per Share NeuroBo Pharmaceuticals|NRBO - Company Book Value|Capitalization to Book Value Ratio neurobopharma.com|NRBO - Company Total Assets
- debt level and financial liquidity data:
Debt to Capital NeuroBo Pharmaceuticals|NRBO - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital NeuroBo Pharma|NRBO - Company Debts|Debt to Net Assets Ratio NeuroBo Pharmaceuticals|NRBO - Company Long-Term Debt|Short-Term Debt NeuroBo Pharmaceuticals|Quick Liquidity neurobopharma.com
- earnings and market multiples details:
NRBO - Company Net Income
Analysis of all company metrics:neurobopharma.com
Manufactured product of NeuroBo

NeuroBo Pharmaceuticals (NRBO) is investing in costly R&D research to combat obesity and liver diseases. The company's long-term debt time series records obligations with maturities exceeding one year, reflecting the financing strategy for these developments. The growth of this metric indicates the acquisition of institutional loans to cover fixed costs. A stable debt level confirms the resilience of the model until the commercialization of patents, which ultimately determines the issuer's cost of capital.

Competitors of NeuroBo Pharmaceuticals (NRBO)

Company Long-Term Debts biogen.com BIIB|NBIX - Company Long-Term Debt|Company Long-Term Loans and Borrowings RGC (Regencell Bioscience Ltd)|Axsome Therapeutics Inc (AXSM) - Company Long-Term Debt|Long-Term Debt ACADIA Corp (ACAD)|Company Long-Term Debt Xenon Pharmaceuticals|Company Long-Term Indebtedness VKTX (vikingtherapeutics.com)|Company Long-Term Debts SUPN|CPRX - Long-Term Debt|Denali Therapeutics Inc - Company Long-Term Liabilities|Company Long-Term Debts Harmony Corp HRMY|BHVN - Company Long-Term Debt|Company Long-Term Loans and Borrowings AMLX (amylyx.com)|Trevi Therapeutics, Inc. (TRVI) - Company Long-Term Debt|Long-Term Debt Praxis Precision Medicines Inc (PRAX)|AVXL (Anavex Corp) - Company Long-Term Debts|Company Long-Term Debt CBLL|Company Long-Term Debt Prothena (PRTA)|ALEC - Long-Term Debt|Annexon - Company Long-Term Liabilities|Company Long-Term Loans and Borrowings OMER|NGNE - Company Long-Term Debt|Long-Term Liabilities ACIU|VYGR: Company Long-Term Debts|neumoratx.com - Company Long-Term Loans and Borrowings|SCLX (Scilex) - Company Long-Term Debts|Company Long-Term Debts Tevogen Bio Holdings Inc.|Company Long-Term Debt Alpha Cognition (ACOG)|CGTX (cogrx.com) - Company Long-Term Loans and Borrowings|Company Long-Term Debt Inhibikase Therapeutics IKT|SAVA - Company Long-Term Liabilities|Assertio Therapeutics - Company Long-Term Debts|COYA - Company Long-Term Debts|VTGN: Company Long-Term Debts|Company Long-Term Liabilities Ovid Therapeutics|ABOS (Acumen Pharmaceuticals) - Company Long-Term Debts|Long-Term Debt cervomed.com CRVO|Company Long-Term Liabilities ATHE (Alterity Therapeutics)|Company Long-Term Debts clene.com (CLNN)|PepGen - Company Long-Term Liabilities|Amount of Long-Term Liabilities JUNS (jupiterneurosciences.com)|Relmada Therapeutics - Company Long-Term Debts|Long-Term Debt Volume annovisbio.com ANVS|GRCE: Company Long-Term Debts|Company Long-Term Liabilities Firefly Neuroscience, Inc.|KLTO (ANEW Medical) - Company Long-Term Debts|Company Long-Term Debts NeuroSense Therapeutics, Ltd.|Company Long-Term Debt Reviva Pharmaceuticals (RVPH)|Company Long-Term Debt MTVA (metaviatx.com)|Company Long-Term Debt NeurAxis NRXS|Long-Term Debt Volume Helius Medical Technologies, Inc. (HSDT)|PASG - Company Long-Term Debt|NEUP (Neuphoria Therapeutics Inc.) - Company Long-Term Indebtedness|Minerva Neurosciences (NERV) - Company Long-Term Debt|athira.com - Company Long-Term Loans and Borrowings|ADXN (Addex Therapeutics Ltd) - Company Long-Term Debts|Company Long-Term Debt ALZN|Company Long-Term Debt Cyclerion Therapeutics (CYCN)|PTIX - Long-Term Debt|Company Long-Term Debt Pasithea Therapeutics Corp. KTTA|CRGT: Company Long-Term Indebtedness|Avenue Therapeutics, Inc. - Company Long-Term Debts|Long-Term Debt Brainstorm Cell Therapeutics Inc.|CARA (Cara Therapeutics, Inc) - Company Long-Term Liabilities|Chromocell (CHRO) - Company Long-Term Debts|Company Long-Term Debt Eliem Therapeutics, Inc.|ITCI: Company Long-Term Loans and Borrowings|Company Long-Term Debt Longboard Pharmaceuticals, Inc. (LBPH)|MRNS - Long-Term Debt|Company Long-Term Debt NKGen NKGN|SAGE: Company Long-Term Indebtedness|Synaptogenix, Inc. - Company Long-Term Debts|Long-Term Debt trevena.com|VIGL (vigilneuro.com) - Company Long-Term Liabilities|Anew Medical Inc. (WENA) - Company Long-Term Debts|Company Long-Term Debt Cerevel